RayKnowChina Research Map
Shortlist

Not yet recruitingPancreatic cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07906691, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 45 years; sex: all

    Registered eligibility fields

  2. Female participants of childbearing potential who have not been surgically sterilized must use highly effective contraception from the time of signing the informed consent form until 1 month after the last dose of HRS-4642; male participants whose partners are women of childbearing potential must use highly effective contraception from the time of signing the informed consent form until 1 month after the last dose of HRS-4642. Female participants of childbearing potential who have not been surgically sterilized must have a negative serum HCG test within 14 days prior to the first dose, and must not be lactating.

    Inclusion criterion 3

    Surgery within 6 months prior to screening, or planned surgery during the study period.

    Exclusion criterion 4

    Regular use of sedatives, hypnotics, or other addictive drugs; a history of drug abuse within 1 year prior to screening, or a positive urine drug abuse screen.

    Exclusion criterion 7

  3. Positive hepatitis B surface antigen (HBsAg), positive hepatitis C antibody (anti-HCV), positive syphilis antibody, or positive HIV antibody.

    Exclusion criterion 12

  4. Pregnant or lactating women.

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07906691, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Healthy participants aged 18 to 45 years (inclusive) at the time of signing the informed consent form.
  • Male participants with body weight ≥ 50.0 kg, female participants with body weight ≥ 45.0 kg, and body mass index (BMI) between 19 and 26 kg/m² (inclusive of both endpoints).
  • Female participants of childbearing potential who have not been surgically sterilized must use highly effective contraception from the time of signing the informed consent form until 1 month after the last dose of HRS-4642; male participants whose partners are women of childbearing potential must use highly effective contraception from the time of signing the informed consent form until 1 month after the last dose of HRS-4642. Female participants of childbearing potential who have not been surgically sterilized must have a negative serum HCG test within 14 days prior to the first dose, and must not be lactating.
  • Participants are able to communicate effectively with the investigator, understand and comply with all requirements of this study, and understand and sign the informed consent form.

Exclusion Criteria:

  • A history of or current presence of any clinically significant disease of the circulatory, endocrine, nervous, digestive, respiratory, urogenital, hematologic, immunologic, or psychiatric systems, or metabolic disorders, or any other condition that may interfere with the study results.
  • Poorly controlled or severe cardiovascular/cerebrovascular disease or arterial/venous thrombotic events within 6 months prior to study entry, such as cerebral hemorrhage, cerebral infarction, severe/unstable angina pectoris, symptomatic congestive heart failure (NYHA Class II-IV), myocardial infarction, arrhythmia requiring clinical intervention, deep vein thrombosis, etc.
  • Carotid ultrasound showing stenosis ≥ 50% (the ECST method is preferred) or presence of more than 2 high-risk plaques.
  • Surgery within 6 months prior to screening, or planned surgery during the study period.
  • Previous surgery affecting gastrointestinal absorption (including gastrectomy, bowel resection, gastric bypass/bariatric surgery, etc.), or need for gastric acid-neutralizing medications (e.g., aluminum hydroxide) during the study.
  • Blood donation or significant blood loss (≥ 400 mL), blood transfusion, or use of blood products within 3 months prior to screening.
  • Regular use of sedatives, hypnotics, or other addictive drugs; a history of drug abuse within 1 year prior to screening, or a positive urine drug abuse screen.
  • Participation in any clinical trial with administration of investigational drugs within 3 months prior to the first dose.
  • Smoking more than 5 cigarettes per day within 3 months prior to screening, and inability to stop using any tobacco products during the study period.
  • Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 285 mL of beer, 25 mL of spirits, or 100 mL of wine), and inability to stop using any alcohol-containing products during the study period; positive breath alcohol test.
  • Clinically significant abnormalities in vital signs, physical examination, 12-lead electrocardiogram (ECG), abdominal ultrasound, chest X-ray, complete blood count, blood biochemistry, urinalysis, or coagulation tests during the screening period.
  • Positive hepatitis B surface antigen (HBsAg), positive hepatitis C antibody (anti-HCV), positive syphilis antibody, or positive HIV antibody.
  • History of needle phobia or blood-injection phobia, difficulty with blood collection, or inability to tolerate venipuncture blood sampling.
  • Pregnant or lactating women.
  • Participants with other factors deemed by the investigator to be unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07906691, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07906691, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07906691